Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 45
Filter
1.
Neurogastroenterol Motil ; 33(1): e14058, 2021 01.
Article in English | MEDLINE | ID: mdl-33373111

ABSTRACT

Chicago Classification v4.0 (CCv4.0) is the updated classification scheme for esophageal motility disorders using metrics from high-resolution manometry (HRM). Fifty-two diverse international experts separated into seven working subgroups utilized formal validated methodologies over two-years to develop CCv4.0. Key updates in CCv.4.0 consist of a more rigorous and expansive HRM protocol that incorporates supine and upright test positions as well as provocative testing, a refined definition of esophagogastric junction (EGJ) outflow obstruction (EGJOO), more stringent diagnostic criteria for ineffective esophageal motility and description of baseline EGJ metrics. Further, the CCv4.0 sought to define motility disorder diagnoses as conclusive and inconclusive based on associated symptoms, and findings on provocative testing as well as supportive testing with barium esophagram with tablet and/or functional lumen imaging probe. These changes attempt to minimize ambiguity in prior iterations of Chicago Classification and provide more standardized and rigorous criteria for patterns of disorders of peristalsis and obstruction at the EGJ.


Subject(s)
Esophageal Motility Disorders/physiopathology , Manometry/methods , Esophageal Achalasia/classification , Esophageal Achalasia/diagnosis , Esophageal Achalasia/physiopathology , Esophageal Achalasia/therapy , Esophageal Motility Disorders/classification , Esophageal Motility Disorders/diagnosis , Esophageal Motility Disorders/therapy , Esophageal Spasm, Diffuse/classification , Esophageal Spasm, Diffuse/diagnosis , Esophageal Spasm, Diffuse/physiopathology , Esophageal Spasm, Diffuse/therapy , Esophagogastric Junction/physiopathology , Humans
2.
Am Fam Physician ; 102(5): 291-296, 2020 09 01.
Article in English | MEDLINE | ID: mdl-32866357

ABSTRACT

Esophageal motility disorders can cause chest pain, heartburn, or dysphagia. They are diagnosed based on specific patterns seen on esophageal manometry, ranging from the complete absence of contractility in patients with achalasia to unusually forceful or disordered contractions in those with hypercontractile motility disorders. Achalasia has objective diagnostic criteria, and effective treatments are available. Timely diagnosis results in better outcomes. Recent research suggests that hypercontractile motility disorders may be overdiagnosed, leading to unnecessary and irreversible interventions. Many symptoms ascribed to these disorders are actually due to unrecognized functional esophageal disorders. Hypercontractile motility disorders and functional esophageal disorders are generally self-limited, and there is considerable overlap among their clinical features. Endoscopy is warranted in all patients with dysphagia, but testing to evaluate for less common conditions should be deferred until common conditions have been optimally managed. Opioid-induced esophageal dysmotility is increasingly prevalent and can mimic symptoms of other motility disorders or even early achalasia. Dysphagia of liquids in a patient with normal esophagogastroduodenoscopy findings may suggest achalasia, but high-resolution esophageal manometry is required to confirm the diagnosis. Surgery and advanced endoscopic therapies have proven benefit in achalasia. However, invasive interventions are rarely indicated for hypercontractile motility disorders, which are typically benign and usually respond to lifestyle modifications, although pharmacotherapy may occasionally be needed.


Subject(s)
Endoscopy, Digestive System , Esophageal Motility Disorders/diagnosis , Esophageal Motility Disorders/therapy , Heller Myotomy/methods , Manometry , Botulinum Toxins, Type A/therapeutic use , Calcium Channel Blockers/therapeutic use , Chest Pain/physiopathology , Deglutition Disorders/physiopathology , Diagnosis, Differential , Dilatation/methods , Esophageal Achalasia/diagnosis , Esophageal Achalasia/physiopathology , Esophageal Achalasia/therapy , Esophageal Motility Disorders/physiopathology , Esophageal Spasm, Diffuse/diagnosis , Esophageal Spasm, Diffuse/physiopathology , Esophageal Spasm, Diffuse/therapy , Esophageal Stenosis/diagnosis , Esophagitis/diagnosis , Gastroesophageal Reflux/diagnosis , Gastroesophageal Reflux/physiopathology , Gastroesophageal Reflux/therapy , Humans , Myotomy/methods , Neuromuscular Agents/therapeutic use , Nitrates/therapeutic use
3.
Acta Med Okayama ; 72(6): 595-600, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30573915

ABSTRACT

The indications for peroral endoscopic myotomy (POEM) have been expanded to include diffuse esophageal spasm (DES). A 67-year-old Japanese man presented with a 4-year history of dysphagia. Endoscopy and upper gastrography revealed abnormal peristaltic movements involving interruption of normal peristalsis, and a diverticulum located at the 2 o'clock esophageal position. High-resolution manometry indicated DES. POEM with a long (15 cm) myotomy was performed for the abnormal contractions, which subsequently disappeared along with dysphagia improvement. Our results suggest that esophageal motility disorders accompanying a diverticulum may be eliminated by POEM without treating the diverticulum itself. We speculate that POEM ameliorates esophageal diverticulum by reducing internal esophageal pressure.


Subject(s)
Endoscopy, Gastrointestinal/methods , Esophageal Spasm, Diffuse/therapy , Myotomy/methods , Aged , Humans , Male
4.
Curr Gastroenterol Rep ; 20(9): 42, 2018 Aug 06.
Article in English | MEDLINE | ID: mdl-30079434

ABSTRACT

PURPOSE OF REVIEW: This review addresses the similarities and differences between the spastic esophageal disorders, including jackhammer esophagus, distal esophageal spasm (DES), and type III (spastic) achalasia. The pathophysiology, diagnosis, and treatment of each separate disorder are discussed herein, with an emphasis on overlapping and discordant features. RECENT FINDINGS: The Chicago Classification is a hierarchical organizational scheme for esophageal motility disorders, currently in its third iteration, with direct impact on the definitions of these three disorders. Complementary diagnostic tools such as impedance planimetry and novel manometric parameters continue to evolve. The suite of potential treatments for these disorders is also expanding, with progressive interest in the role of peroral endoscopic myotomy alongside established pharmacologic and mechanical interventions. Although jackhammer esophagus, distal esophageal spasm, and type III achalasia frequently overlap in terms of their clinical presentation and available management approaches, the divergences in their respective diagnostic criteria suggest that additional study may reveal additional mechanistic distinctions that lead in turn to further refinements in therapeutic decision-making.


Subject(s)
Esophageal Motility Disorders/classification , Esophageal Motility Disorders/diagnosis , Esophageal Motility Disorders/physiopathology , Esophageal Motility Disorders/therapy , Esophageal Spasm, Diffuse/classification , Esophageal Spasm, Diffuse/diagnosis , Esophageal Spasm, Diffuse/physiopathology , Esophageal Spasm, Diffuse/therapy , Humans
5.
Am J Med ; 131(9): 1034-1040, 2018 09.
Article in English | MEDLINE | ID: mdl-29605413

ABSTRACT

Distal esophageal spasm is a rare motility disorder presenting principally with nonobstructive dysphagia and noncardiac chest pain. In symptomatic patients, the manometric diagnosis is made when >10% of the wet swallows have simultaneous and/or premature contractions intermixed with normal peristalsis. We characterize manometry and barium as complementary diagnostic approaches, and given the intermittent nature of the disorder, one should be always aware that it is almost impossible to rule out spasm. Treatment is difficult; we propose an approach beginning with the least invasive intervention.


Subject(s)
Esophageal Spasm, Diffuse/complications , Esophageal Spasm, Diffuse/therapy , Antidepressive Agents, Tricyclic/therapeutic use , Barium Radioisotopes , Botulinum Toxins/therapeutic use , Calcium Channel Blockers/therapeutic use , Esophageal Achalasia/complications , Esophageal Spasm, Diffuse/diagnosis , Gastroesophageal Reflux/complications , Humans , Isosorbide Dinitrate/therapeutic use , Manometry , Mentha piperita , Myotomy , Nitric Oxide Donors/therapeutic use , Phosphodiesterase 5 Inhibitors/therapeutic use , Plant Oils/therapeutic use , Prevalence , Proton Pump Inhibitors/therapeutic use , Terminology as Topic
6.
Rev. esp. enferm. dig ; 109(8): 578-586, ago. 2017. ilus, tag
Article in English | IBECS | ID: ibc-165160

ABSTRACT

Introduction: Peroral endoscopic myotomy (POEM) has been performed since 2008 on more than 5,000 patients. It has proven to be highly effective in the treatment of achalasia and has shown promising outcomes for other esophageal motility spastic disorders. Methods: A literature review of the efficacy of POEM compared to the previous invasive treatments for different esophageal motility disorders was performed. The application in the pediatric and elderly populations and its role as a rescue therapy after other procedures are also outlined. Results: Short-term outcomes are similar to laparoscopic Heller myotomy (LHM) and pneumatic endoscopic dilation (PD) (clinical success > 90%) for achalasia subtypes I and II. Mid-term outcomes are comparable to LHM and overcome results obtained after PD (> 90% vs ~50%). With regard to type III achalasia, POEM efficacy is 98% compared to 80.8% for LHM and the PD success remains at 40%. With regard to spastic esophageal disorders (SED), POEM has an effectiveness of 88% and 70% for distal esophageal spasm (DES) and jackhammer esophagus (JE) respectively. A response of 95% in patients with sigmoid esophagus has been reported. POEM has been performed in pediatric and elderly populations and has obtained a higher efficacy than PD in pediatric series (100% vs 33%) without greater adverse events. Previous treatments do not seem to hinder POEM results with excellent response rates, including 97% in post LHM and 100% in a re-POEM series. Final considerations: POEM has shown excellent short and mid-term results for all subtypes of achalasia but long-term results are not yet available. The promising results in SED may make POEM the first-line treatment for SED. A high-safety profile and efficacy have been shown in elderly and pediatric populations. Previous treatments do not seem to diminish the success rate of POEM. Core tip: POEM has emerged as an efficient treatment option for all subtypes of achalasia and other scenarios (including previous treatments and elderly and pediatric populations). Short and midterm results are comparable to LHM and are better than PD data. The clinical response rate of DES and JE may make POEM the first-line treatment for SED (AU)


No disponible


Subject(s)
Humans , Esophageal Diseases/complications , Esophageal Diseases/diagnosis , Esophageal Achalasia/complications , Esophageal Spasm, Diffuse/complications , Endoscopy/methods , Gastrointestinal Motility , Esophageal Motility Disorders , Esophageal Spasm, Diffuse/therapy , Esophageal Motility Disorders/diagnosis , Esophageal Motility Disorders/therapy , Esophageal Achalasia/diagnosis , Diverticulum, Esophageal/complications , Diverticulum, Esophageal , Manometry
7.
Curr Gastroenterol Rep ; 19(8): 37, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28730503

ABSTRACT

PURPOSE OF REVIEW: High-resolution manometry (HRM) is increasingly performed worldwide, to study esophageal motility. The Chicago classification is subsequently applied to interpret the manometric findings and facilitate a diagnosis of esophageal motility disorders. This review will discuss new insights regarding the diagnosis and management using the Chicago classification. RECENT FINDINGS: Recent studies have demonstrated that high-resolution manometry is superior to conventional manometry, and has a higher sensitivity to diagnose achalasia. Furthermore, the subclassification of achalasia as used in the Chicago classification has prognostic value and can be used to direct treatment. Diagnosis of esophageal spasm has been improved by using the distal latency as diagnostic criterion. Recently, criteria for minor disorders of peristalsis have been sharpened, leading to a lower rate of patients with abnormal results, thereby increasing the relevance of a diagnosis. High-resolution manometry is now considered the gold standard for diagnosis of esophageal motility disorders. The Chicago classification provides a standardized approach for analysis and categorization of abnormalities that has led to a significant increase in our knowledge regarding the diagnosis and management of motility disorders. Further refinement of the classification will be required.


Subject(s)
Esophageal Motility Disorders/classification , Manometry/methods , Chicago , Esophageal Achalasia/classification , Esophageal Achalasia/diagnosis , Esophageal Achalasia/therapy , Esophageal Motility Disorders/diagnosis , Esophageal Motility Disorders/therapy , Esophageal Spasm, Diffuse/classification , Esophageal Spasm, Diffuse/diagnosis , Esophageal Spasm, Diffuse/therapy , Humans , Manometry/standards , Peristalsis , Sensitivity and Specificity
8.
Clin Med (Lond) ; 15(5): 477-81, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26430190

ABSTRACT

Acute oesophageal symptoms include acute dysphagia or food bolus impaction (most commonly due to strictures, Schatzki ring and eosinophilic oesophagitis), acute chest pain with odynophagia due to oesophageal infections, motility disorders and acute oesophageal rupture (of which oesophageal intramural haematoma is a subtype). Acute full thickness oesophageal rupture carries a high mortality if not recognised early; the clinical features and conditions with which this may be confused are presented and discussed.


Subject(s)
Esophageal Diseases , Acute Disease , Esophageal Achalasia/therapy , Esophageal Diseases/etiology , Esophageal Diseases/therapy , Esophageal Motility Disorders , Esophageal Spasm, Diffuse/therapy , Hematoma/pathology , Humans , Infections/diagnosis , Rupture, Spontaneous
9.
Curr Opin Gastroenterol ; 31(4): 328-33, 2015 Jul.
Article in English | MEDLINE | ID: mdl-26039725

ABSTRACT

PURPOSE OF REVIEW: Distal esophageal spasm (DES) is a rare esophageal motility disorder associated with dysphagia and chest pain. In 2011, the diagnosis of DES was refined based on the occurrence of premature (rather than rapid) contractions by high-resolution manometry. New therapeutic options have also been recently proposed. Thus, a review on DES incorporating publications since 2012 is timely because of these revisions in definition and management. RECENT FINDINGS: DES remains a heterogeneous clinical disorder. Its pathophysiology is still debated and DES might be related to achalasia. Alternatively, it might be secondary to medications, especially opiates. Endoscopic ultrasound might be informative diagnostically by demonstrating muscularis propria hypertrophy and thickening. Botulinum toxin injection in the esophageal body has been shown superior to placebo to relieve symptoms associated with DES. Finally, per oral endoscopic myotomy is a promising therapeutic approach, but may be less effective in DES than in achalasia. SUMMARY: The diagnosis of DES should lead to a systematic search for medication that might promote the occurrence of esophageal dysmotility. Endoscopic treatment of DES (botulinum toxin injection or per oral endoscopic myotomy) should be further evaluated in controlled studies using current diagnostic criteria by high-resolution manometry.


Subject(s)
Esophageal Spasm, Diffuse/diagnosis , Esophageal Spasm, Diffuse/therapy , Botulinum Toxins/therapeutic use , Endosonography/methods , Esophageal Spasm, Diffuse/etiology , Esophageal Spasm, Diffuse/physiopathology , Esophageal Sphincter, Lower/surgery , Esophagus/physiopathology , Humans , Manometry/methods , Natural Orifice Endoscopic Surgery/methods , Neurotoxins/therapeutic use
10.
Eksp Klin Gastroenterol ; (2): 32-5, 2014.
Article in Russian | MEDLINE | ID: mdl-25518472

ABSTRACT

The article describes the diffuse esophageal spasm which is not amenable to conservative treatment.


Subject(s)
Esophageal Spasm, Diffuse/diagnosis , Esophageal Spasm, Diffuse/parasitology , Esophageal Spasm, Diffuse/therapy , Adult , Humans
11.
Curr Gastroenterol Rep ; 16(11): 421, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25376746

ABSTRACT

Esophageal hypomotility (EH) is characterized by abnormal esophageal peristalsis, either from a reduction or absence of contractions, whereas spastic motor disorders (SMD) are characterized by an increase in the vigor and/or propagation velocity of esophageal body contractions. Their pathophysiology is not clearly known. The reduced excitation of the smooth muscle contraction mediated by cholinergic neurons and the impairment of inhibitory ganglion neuronal function mediated by nitric oxide are likely mechanisms of the peristaltic abnormalities seen in EH and SMD, respectively. Dysphagia and chest pain are the most frequent clinical manifestations for both of these dysfunctions, and gastroesophageal reflux disease (GERD) is commonly associated with these motor disorders. The introduction of high-resolution manometry (HRM) and esophageal pressure topography (EPT) has significantly enhanced the ability to diagnose EH and SMD. Novel EPT metrics in particular the development of the Chicago Classification of esophageal motor disorders has enabled improved characterization of these abnormalities. The first step in the management of EH and SMD is to treat GERD, especially when esophageal testing shows pathologic reflux. Smooth muscle relaxants (nitrates, calcium channel blockers, 5-phosphodiesterase inhibitors) and pain modulators may be useful in the management of dysphagia or pain in SMD. Endoscopic Botox injection and pneumatic dilation are the second-line therapies. Extended myotomy of the esophageal body or peroral endoscopic myotomy (POEM) may be considered in highly selected cases but lack evidence.


Subject(s)
Esophageal Motility Disorders/diagnosis , Esophageal Motility Disorders/therapy , Esophageal Spasm, Diffuse/diagnosis , Esophageal Spasm, Diffuse/therapy , Esophageal pH Monitoring , Esophagoscopy/methods , Humans , Manometry/methods , Peristalsis/physiology
12.
Curr Gastroenterol Rep ; 15(9): 325, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23892829

ABSTRACT

Distal esophageal spasm (DES) is an esophageal motility disorder that presents clinically with chest pain and/or dysphagia and is defined manometrically as simultaneous contractions in the distal (smooth muscle) esophagus in ≥20% of wet swallows (and amplitude contraction of ≥30 mmHg) alternating with normal peristalsis. With the introduction of high resolution esophageal pressure topography (EPT) in 2000, the definition of DES was modified. The Chicago classification proposed that the defining criteria for DES using EPT should be the presence of at least two premature contractions (distal latency<4.5 s) in a context of normal EGJ relaxation. The etiology of DES remains insufficiently understood, but evidence links nitric oxide (NO) deficiency as a culprit resulting in a disordered neural inhibition. GERD frequently coexists in DES, and its role in the pathogenesis of symptoms needs further evaluation. There is some evidence from small series that DES can progress to achalasia. Treatment remains challenging due in part to lack of randomized placebo-controlled trials. Current treatment agents include nitrates (both short and long acting), calcium-channel blockers, anticholinergic agents, 5-phosphodiesterase inhibitors, visceral analgesics (tricyclic agents or SSRI), and esophageal dilation. Acid suppression therapy is frequently used, but clinical outcome trials to support this approach are not available. Injection of botulinum toxin in the distal esophagus may be effective, but further data regarding the development of post-injection gastroesophageal reflux need to be assessed. Heller myotomy combined with fundoplication remains an alternative for the rare refractory patient. Preliminary studies suggest that the newly developed endoscopic technique of per oral endoscopic myotomy (POEM) may also be an alternative treatment modality.


Subject(s)
Esophageal Spasm, Diffuse/diagnosis , Algorithms , Dilatation/methods , Disease Progression , Esophageal Achalasia/surgery , Esophageal Spasm, Diffuse/etiology , Esophageal Spasm, Diffuse/therapy , Esophageal Sphincter, Lower/surgery , Gastrointestinal Agents/therapeutic use , Humans , Manometry/methods
13.
Gastroenterol Clin North Am ; 42(1): 27-43, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23452629

ABSTRACT

The concept of esophageal spastic disorders encompasses spastic achalasia, distal esophageal spasm, and jackhammer esophagus. These are conceptually distinct in that spastic achalasia and distal esophageal spasm are characterized by a loss of neural inhibition, whereas jackhammer esophagus is associated with hypercontractility. Hypercontractility may also occur as a result of esophagogastric junction outflow obstruction or inflammation. The diagnosis of jackhammer esophagus as a primary motility disorder is based on the characteristic manometric findings after ruling out mechanical obstruction and eosinophilic esophagitis. Despite the differences in pathophysiology among the esophageal spastic disorders, their management is similar.


Subject(s)
Esophageal Achalasia/diagnosis , Esophageal Spasm, Diffuse/diagnosis , Botulinum Toxins, Type A/therapeutic use , Calcium Channel Blockers/therapeutic use , Dilatation/methods , Esophageal Achalasia/therapy , Esophageal Motility Disorders/diagnosis , Esophageal Motility Disorders/therapy , Esophageal Spasm, Diffuse/therapy , Esophageal Sphincter, Lower/surgery , Esophagoscopy , Humans , Manometry , Nitrates/therapeutic use , Phosphodiesterase 5 Inhibitors/therapeutic use
15.
Korean J Gastroenterol ; 60(2): 109-12, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22926122

ABSTRACT

Diffuse esophageal spasm, an uncommon esophageal motility disorder, has recently been defined using high-resolution manometry. Patients with distal esophageal spasm usually complain of chest pain or dysphagia. The etiology and pathophysiology of this disorder are poorly known, and treatment options are limited. However, some options to improve symptoms are available, including endoscopic injection of botulinum toxin. Nevertheless, few reports have described the effects of endoscopic injection of botulinum toxin in patients with symptomatic diffuse esophageal spasm with clear endoscopic and high-resolution manometry images. Here, we report a case of diffuse esophageal spasm diagnosed with high-resolution manometry and treated by endoscopic injection of botulinum toxin with good results at the 7-month follow-up.


Subject(s)
Anti-Dyskinesia Agents/therapeutic use , Botulinum Toxins/therapeutic use , Esophageal Spasm, Diffuse/therapy , Aged , Endoscopy, Digestive System , Esophageal Spasm, Diffuse/diagnostic imaging , Female , Humans , Manometry , Tomography, X-Ray Computed
16.
J Clin Gastroenterol ; 46(6): 442-8, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22688141

ABSTRACT

High-resolution manometry has added significantly to our current understanding of esophageal motor function by providing improved detail and a data analysis paradigm that is more akin to an imaging format. Esophageal pressure topography provides a seamless dynamic representation of the pressure profile through the entire esophagus and thus, is able to eliminate movement artifact and also assess intrabolus pressure patterns as a surrogate for bolus transit mechanics. This has led to improved identification of anatomic landmarks and measurement of important physiological parameters (esophagogastric junction relaxation, distal latency, and contractile integrity). This research has bridged the gap into clinical practice by defining physiologically relevant phenotypes that may have prognostic significance and improve treatment decisions in achalasia, spasm, and hypercontractile disorders. However, more work is needed in determining the etiology of symptom generation in the context of normal or trivial motor dysfunction. This research will require new techniques to assess visceral hypersensitivity and alterations in central modulation of pain and discomfort.


Subject(s)
Esophageal Motility Disorders/diagnosis , Esophagogastric Junction/metabolism , Manometry/methods , Esophageal Achalasia/diagnosis , Esophageal Achalasia/physiopathology , Esophageal Achalasia/therapy , Esophageal Motility Disorders/physiopathology , Esophageal Motility Disorders/therapy , Esophageal Spasm, Diffuse/diagnosis , Esophageal Spasm, Diffuse/physiopathology , Esophageal Spasm, Diffuse/therapy , Humans , Muscle Contraction , Pressure
17.
Dysphagia ; 27(1): 115-23, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22215281

ABSTRACT

Distal esophageal spasm (DES) is an uncommon esophageal motility disorder associated with dysphagia and/or chest pain. Its pathophysiology implies an impairment of esophageal inhibitory neural function. Using conventional manometry, DES was defined by the presence of simultaneous esophageal contractions. With the introduction of high-resolution manometry and esophageal pressure topography (EPT) in clinical practice, rapidly propagated contractions are nonspecific of esophageal spasm. Hence, a more physiological and clinically relevant definition was proposed. Distal latency (DL) measures the period of inhibition that precedes contraction in the distal esophagus immediately proximal to the esophagogastric junction (EGJ). Premature contractions, defined as reduced DL, appeared to be much more specific for DES in EPT. Premature contractions with normal EGJ relaxation constitute DES, while premature contractions with impaired EGJ relaxation are diagnostic of spastic achalasia. Because of the interaction between DES and gastroesophageal reflux disease, 24-h esophageal pH monitoring should also be considered in patient evaluation. Medical treatment of DES aims to compensate for the deficient inhibitory neural function. Sildenafil, which blocks nitric oxide degradation and thus prolongs esophageal muscle relaxation, is a promising treatment. Endoscopic injection of botulinum toxin in the esophageal muscle is also an interesting therapeutic option. Finally, extended surgical myotomy might be discussed in extreme cases after failure of other therapeutic options.


Subject(s)
Esophageal Spasm, Diffuse , Anti-Dyskinesia Agents/therapeutic use , Barium , Botulinum Toxins/therapeutic use , Contrast Media , Endoscopy , Esophageal Spasm, Diffuse/diagnosis , Esophageal Spasm, Diffuse/physiopathology , Esophageal Spasm, Diffuse/therapy , Esophagus/physiopathology , Esophagus/surgery , Gastrointestinal Agents/therapeutic use , Humans , Manometry , Phosphodiesterase 5 Inhibitors/therapeutic use , Piperazines/therapeutic use , Purines/therapeutic use , Sildenafil Citrate , Sulfones/therapeutic use
19.
Drug Ther Bull ; 49(5): 54-7; quiz i-ii, 2011 May.
Article in English | MEDLINE | ID: mdl-21543371

ABSTRACT

Non-cardiac chest pain is common,1 affecting around 25% of the population during their lifetime and accounting for about 2-5% of presentations to hospital accident and emergency departments.2 Around 10% of patients presenting with such pain, and up to 13% of those presenting with functional dysphagia, have diffuse oesophageal spasm (DOS), an oesophageal motility disorder.3,4 DOS is often recognised and treated only after patients have attended hospital emergency departments and specialist clinics for years, because of the non-specific nature of their symptoms and difficulty in diagnosis (features common to motility disorders).5 Here we discuss the diagnosis and further management of patients with DOS.


Subject(s)
Esophageal Spasm, Diffuse/therapy , Antidepressive Agents/therapeutic use , Botulinum Toxins, Type A/therapeutic use , Counseling , Esophageal Spasm, Diffuse/diagnosis , Esophageal Spasm, Diffuse/physiopathology , Humans , Life Style , Neuromuscular Agents/therapeutic use , Parasympatholytics/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...